Sygnis Pharma AG expects that initial results from its multinational Phase 2 efficacy study of the stroke treatment, AX200, will be available in mid-2011. The German company issued the forecast with the release of its fiscal 2009/2010 results. ---Subscribe to MedNous to access this article--- Company News
